Sanofi unit loses genetic disorder patent at EPO after trio of challenges
Boards of Appeal revokes Genzyme patent, handing win to Accord Healthcare | Teva and Hetero Labs also previously filed oppositions | Patent refers to Cerdelga, part of Sanofi’s Gaucher disease franchise.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
13 May 2025 Court of First Instance rules on Sanofi v Amgen antibodies dispute | Claims dismissed as “unfounded” and lacking in evidence | All parties ordered to pay costs totalling €45m ($50m).
28 January 2025 Munich division asks pharma company for clarity on territorial scope | Sanofi took battle with four generic makers over Jevtana to UPC.